Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

January 3, 2024

https://www.globenewswire.com/news-release/2024/01/03/2803233/0/en/Keros-Therapeutics-to-Develop-KER-065-for-the-Treatment-of-Obesity.html

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it plans to develop KER-065, a novel ligand trap designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A, for the treatment of obesity.

Read more at globenewswire.com

Related news for (KROS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.